Surrozen, Inc. SRZN
At closeNov 10, 2026, 4:41 PM EST
After hours · Nov 10, 4:41 PM ET
- YTD
- +44.42%
- 1 year
- +176.61%
- Market cap
- 571.04M
- Revenue (ttm)
- 10.00M
- EPS (ttm)
- -41.94
- Shares out
- 3.25M
- Forward P/E
- -2.75
- YTD return
- +44.42%
- 1-year return
- +176.61%
- Volume
- 197.90K
- Avg volume
- 539.30K
- Open
- 32.63
- Previous close
- 32.00
- Day's range
- 31.23 – 33.62
- 52-week range
- 11.73 – 37.83
- Price target
- 33.00 (+1.1%)
- Earnings date
- Aug 12, 2024
5D +0.23 (+0.71%)
Key statistics
- Enterprise value
- 4.62M
- PEG ratio
- 0.00
- Price / sales
- 3.97
- Price / book
- 6.96
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 31.01M
- Total debt
- 1.53M
- Return on equity
- -173.59%
- Short % of float
- 1.40%
- 50-day average
- 10.18
- 200-day average
- 10.09
Analyst view
- Strong buy0
- Buy1
- Hold1
- Sell0
- Strong sell0
Next earnings
Aug 12, 2024
Expected Aug 12, 2024. Consensus EPS estimate -2.64.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | -2.77 | -0.44 | +2.33 | +84.12% |
| Aug 12, 2024 | Jun 1, 2024 | -2.79 | — | — | — |
| Aug 12, 2024 | Jun 1, 2024 | -2.79 | -1.54 | +1.25 | +44.80% |
| May 8, 2024 | Mar 1, 2024 | -4.25 | -4.24 | +0.01 | +0.24% |
| May 8, 2024 | Mar 1, 2024 | -4.25 | — | — | — |
| Apr 3, 2024 | Dec 1, 2023 | -4.35 | — | — | — |
About Surrozen, Inc.
Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- surrozen.com
News
Cantor Fitzgerald Maintains Overweight on Surrozen, Raises Price Target to $62 
Surrozen Reports Third Quarter 2026 Financial Results and Provides Business Update 
Surrozen to Present at Upcoming Healthcare Investor Conference 
Surrozen Announces Closing of Second Tranche of March 2025 Private Placement for $95.1 Million 
Head to Head Review: Surrozen (NASDAQ:SRZN) and Prelude Therapeutics (NASDAQ:PRLD) 
Surrozen (NASDAQ:SRZN) & Whitehawk Therapeutics (NASDAQ:WHWK) Financial Comparison 
Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema 
Scholastic Posts Downbeat Q1 Results, Joins Legacy Education, Zscaler And Other Big Stocks Moving Lower In Friday’s Pre-Market Session 
HC Wainwright & Co. Maintains Buy on Surrozen, Raises Price Target to $54 
Why INLIF Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
Your note
Sign in to keep a note on SRZN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| COLUMN GROUP III GP, L.P | Beneficial Owner of more than 10% of a Class of Security | Purchase | Apr 3, 2024 | 0 |
| KUTZKEY TIM PH.D. | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Apr 3, 2024 | 0 |
| LI YANG | Officer | Stock Award(Grant) | Jun 13, 2024 | 10,888 |
| PARKER CRAIG C | Chief Executive Officer | Stock Award(Grant) | Jun 13, 2024 | 5,824 |
| WILLIAMS CHARLES O | Chief Operating Officer | Stock Award(Grant) | Jun 13, 2024 | 5,863 |
| YEH WEN-CHEN M.D., PH.D. | Officer | Stock Award(Grant) | Jun 14, 2023 | 27,216 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Column Group LLC | 24.93% | 810,088 | 9.91M | Sep 29, 2024 |
| RA Capital Management, L.P. | 8.70% | 282,580 | 3.46M | Sep 29, 2024 |
| Nantahala Capital Management, LLC | 5.76% | 187,206 | 2.29M | Sep 29, 2024 |
| Stempoint Capital LP | 5.63% | 182,918 | 2.24M | Sep 29, 2024 |
| Armistice Capital, LLC | 4.28% | 139,000 | 1.70M | Sep 29, 2024 |
| Stonepine Capital Management, LLC | 3.38% | 110,000 | 1.35M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.43% | 46,578 | 569.65K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.56% | 18,127 | 221.69K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.34% | 10,983 | 134.32K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.16% | 5,269 | 64.44K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.08% | 2,745 | 33.57K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.08% | 2,592 | 31.70K | Oct 30, 2024 |